The US Justice Department sued Walmart over its role in the opioid crisis, alleging irresponsible handling of orders, wrongly filling thousands of prescriptions, and ignoring warning signs about problem orders to boost sales.
Up to billions of dollars in penalties could be sought in the litigation that followed a multi-year investigation.
According to Jeffrey Bossert Clark, acting head of the Justice Department's civil division, Walmart had the responsibility and the means to help prevent the diversion of prescription opioids but instead did the opposite by filling thousands of invalid prescriptions and failing to report suspicious opioid orders.
The government lawsuit said Walmart managers enormously pressured pharmacists to fill prescriptions and that it withheld the information from pharmacists on data on invalid controlled-substance prescriptions.
Walmart claimed the charges were baseless and accused US authorities of shifting blame from the Drug Enforcement Administration's failures in keeping bad doctors from prescribing opioids. It added that the complaint was "riddled with factual inaccuracies."
According to the Centers for Disease Control and Prevention, nearly 450,000 Americans died between 1999 and 2018 from overdoses due to prescription and illegal opioids.


FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 



